Navigation Links
Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
Date:4/23/2009

LOS ANGELES (April 23, 2009) The Food and Drug Administration (FDA) gave its approval this week for Emmaus Medical, Inc. to begin a Phase 3 clinical trial of an experimental treatment for sickle cell disease. The patented experimental treatment was originally developed by investigators led by Yutaka Niihara, MD, MPH, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and is licensed to Emmaus Medical.

The patented drug treatment involves the oral administration of L-glutamine, which is the most common amino acid in the body. This is one of a very few experimental treatments for sickle cell disease to reach the Phase 3 clinical trial stage.

"News of this clinical trial should be of great interest to the millions of people around the world who suffer from painful crises caused by sickle cell disease," said Dr. Niihara. "Phase 3 clinical trials are large, randomized studies conducted at multiple sites to determine the safety and efficacy of a potential treatment. Phase 3 clinical trials are usually the last clinical trials conducted before FDA approval is obtained and the treatment can be made widely available to the patient population."

Sickle cell disease is an inherited disorder that causes red blood cells to become oxidized, sticky and sickle shaped instead of smooth, pliable and round. Sickle cell disease leads to anemia, organ damage, chronic and acute pain and a host of other problems.

"In our Phase 2 clinical trial, we observed an excellent safety profile and positive trends in reducing the number of crises and hospitalizations in sickle cell disease patients," said Dr. Niihara. "We look forward to initiating the Phase 3 clinical trial and remain committed to developing a treatment for sickle cell disease."


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert  

Page: 1

Related medicine news :

1. Anticlotting drug found to be safe in sickle cell patients
2. New Kind of Stem Cells Reverse Sickle Cell Anemia
3. Children with sickle cell disease, silent strokes show some relief with blood transfusions
4. Sickle Cell Disease Pain Can Occur Daily and Is Much More Severe Than Previously Thought
5. Sickle Cell Patients in More Pain Than Thought
6. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
7. For children with sickle cell disease, lung disease is part of the package
8. Lung Trouble Associated With Sickle Cell in Kids
9. Researchers Develop Stem Line With Sickle Cell Mutation
10. Effective treatment for sickle cell underused by doctors
11. Sickle Cell Drug Underused by Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... Oct. 10, 2017   West Pharmaceutical Services, Inc. ... for injectable drug administration, today shared the results of ... for improving the intradermal administration of polio vaccines. The ... Summit in May 2017 by Dr. Ondrej Mach ... World Health Organization (WHO), and recently published in the ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: